Highlights Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-08 pm EDT			5-day change	1st Jan Change
6.280 ^USD	-1.72%		-10.29%	-28.80%

May. 07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

Highlights

May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI
May. 06	Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 01	Vanda Pharmaceuticals Inc. Announces Commercial Availability of Nereus (Tradipitant) for Motion Sickness Prevention in the United States	CI
Apr. 09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT
Apr. 08	Vanda Pharmaceuticals Inc. Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS? for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	CI
Mar. 03	Vanda Pharmaceuticals Inc. Announces FDA Grants Landmark Hearing for HETLIOZin Jet Lag Disorder	CI
Mar. 03	Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years	RE
Mar. 03	Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag	MT
Feb. 27	European Medicines Agency Panel Issues Negative Opinion on Vanda's Schizophrenia Treatment	MT
Feb. 25	Vanda Pharmaceuticals Announces Fda Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	CI
Feb. 25	Vanda Pharmaceuticals announces FDA acceptance of Biologics License Application filing for Imsidolimab for the treatment of generalized pustular psoriasis	RE
Feb. 20	US FDA approves Vanda's psychiatric drug	RE
Feb. 20	Vanda Pharmaceuticals Announces FDA Approval of BYSANTI (milsaperidone) for the Treatment of Bipolar I Disorder and Schizophrenia	CI
Feb. 11	Vanda Pharmaceuticals Inc. Provides Earnings Guidance for the Full Year 2026	CI
Feb. 11	Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Jan. 08	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ®? Supplemental New Drug Application for Jet Lag Disorder	CI
Jan. 08	Top Premarket Decliners	MT
Dec. 31	Top Midday Gainers	MT
Dec. 31	Vanda Pharmaceuticals Says FDA Has Approved Nereus for Motion-Induced Vomiting; Shares Rise Pre-Bell	MT
Dec. 31	Vanda Pharmaceuticals Announces FDA Approval of Nereus? (tradipitant) for the Prevention of Vomiting Induced by Motion	CI
Dec. 26	Top Premarket Gainers	MT
Dec. 15	Vanda Pharmaceuticals Inc. Announces Submission of Biologics License Application to FDA for Imsidolimab for Treatment of Generalized Pustular Psoriasis	CI
Dec. 15	Vanda Pharmaceuticals Submits Biologics License Application to US FDA for Generalized Pustular Psoriasis Drug	MT
Dec. 15	Vanda announces submission of biologics license application to the FDA for Imsidolimab for the treatment of generalized pustular psoriasis	RE
Dec. 04	Vanda Pharmaceuticals Inc. Announces that FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	CI